Score Overview
See the full market ranking โ
Allogene Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 38M to $ 0.00 and net income went from -$ 233M to -$ 190M. Revenue increased in 0 of those 5 years; net income in 4.
Allogene Therapeutics Inc currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.07 | โ |
1 Year2025-08-12 | $ 1.03 | 100.97% |
5 Years2021-08-12 | $ 21.17 | -90.22% |
All Time2018-10-11 | $ 25.00 | -91.72% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2018-10-11 |
|---|---|---|---|---|
| Price | $ 2.07 | $ 1.03 | $ 21.17 | $ 25.00 |
| Return | โ | 100.97% | -90.22% | -91.72% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 173M | $ 266M |
| 2025 | $ 0.00 | -$ 190M | $ 250M |
| 2024 | $ 22K | -$ 257M | $ 292M |
| 2023 | $ 95K | -$ 327M | $ 448M |
| 2022 | $ 243K | -$ 329M | $ 517M |
| 2021 | $ 38M | -$ 244M | $ 457M |
| 2020 | $ 38M | -$ 233M | $ 827M |
| 2019 | $ 0.00 | -$ 184M | $ 530M |
| IPO2018 | $ 0.00 | -$ 211M | $ 721M |
Explore beyond ALLO
You're looking at Allogene Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score โ 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
